<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00297830</url>
  </required_header>
  <id_info>
    <org_study_id>AAAB2324</org_study_id>
    <secondary_id>CZOL446H104</secondary_id>
    <nct_id>NCT00297830</nct_id>
  </id_info>
  <brief_title>Zoledronic Acid Versus Alendronate for Prevention of Bone Loss After Organ Transplantation</brief_title>
  <acronym>CTX</acronym>
  <official_title>Zoledronic Acid Versus Alendronate for Prevention of Bone Loss After Organ Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Columbia University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the effectiveness and safety of zoledronic acid with
      alendronate in the prevention of bone loss after organ transplantation. Zoledronic acid is
      given as a single intravenous infusion. Alendronate is given as a weekly pill. Both are
      expected to be very effective, but it is not known which one will work best.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients who have undergone heart or liver transplantation are usually required to remain on
      medications, such as Prednisone and Cyclosporine A or Tacrolimus, that prevent the body from
      rejecting the transplanted organ. These medications may cause bone loss which leads to
      thinning of the bones (osteoporosis) and therefore greatly increase the risk of having broken
      bones (fractures) after transplantation. Several published studies have shown that 14% to 35%
      of heart transplant patients develop fractures (spine, ribs and hip) during the first year
      after transplantation. We have previously shown that alendronate (Fosamax), a drug approved
      by the FDA for prevention and treatment of postmenopausal osteoporosis and prednisone-induced
      osteoporosis, prevents bone loss after heart transplantation. We are conducting this study to
      determine whether a newer drug, zoledronic acid, is as effective as alendronate.

      This study is a randomized, double-blind, placebo-controlled 2-year study. Participants will
      receive one dose of active zoledronic acid during the first month after heart or liver
      transplantation and weekly placebo alendronate pills or one dose of placebo zoledronic acid
      and weekly active alendronate pills for the first year after transplant. Over 2 years,
      participants will provide blood samples on nine occasions. Bone density will be performed 4-5
      times and spine xrays will be performed twice.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2005</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage Change From Baseline in Total Hip Bone Mineral Density (BMD) at 12 Months</measure>
    <time_frame>Baseline, 12 months</time_frame>
    <description>BMD was measured by dual-energy x-ray absorptiometry (QDR-4500 densitometer; Hologic, Inc., Bedford, MA); short-term in vivo coefficient of variation is 0.68% (spine) and 1.36% (femoral neck). T scores were generated using gender-specific databases provided by the manufacturer.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage Change From Baseline in Lumbar Spine Bone Mineral Density (BMD) at 12 Months</measure>
    <time_frame>Baseline, 12 months</time_frame>
    <description>BMD was measured by dual-energy x-ray absorptiometry (QDR-4500 densitometer; Hologic, Inc., Bedford, MA); short-term in vivo coefficient of variation is 0.68% (spine) and 1.36% (femoral neck). T scores were generated using gender-specific databases provided by the manufacturer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Change From Baseline in Femoral Neck Bone Mineral Density (BMD) at 12 Months</measure>
    <time_frame>Baseline, 12 months</time_frame>
    <description>BMD was measured by dual-energy x-ray absorptiometry (QDR-4500 densitometer; Hologic, Inc., Bedford, MA); short-term in vivo coefficient of variation is 0.68% (spine) and 1.36% (femoral neck). T scores were generated using gender-specific databases provided by the manufacturer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum N-telopeplide Percent Change</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">111</enrollment>
  <condition>Heart Transplantation</condition>
  <condition>Liver Transplantation</condition>
  <condition>Bone Resorption</condition>
  <arm_group>
    <arm_group_label>Active Zoledronic Acid &amp; Placebo Alendronate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 1 will receive an infusion of active zoledronic acid 5 mg during the first 4 weeks after transplantation. Placebo alendronate 70 mg once weekly will be initiated at the same time as the first zoledronic acid infusion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Zoledronic Acid &amp; Active Alendronate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 2 will receive an infusion of placebo zoledronic acid during the first 5 weeks after transplantation. Active alendronate 70 mg once weekly will be initiated at the same time as the placebo infusion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zoledronic acid</intervention_name>
    <description>Drug is administered through 5 mg intravenous infusion over 20 minutes</description>
    <arm_group_label>Active Zoledronic Acid &amp; Placebo Alendronate</arm_group_label>
    <other_name>Zometa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alendronate</intervention_name>
    <description>Alendronate 70 mg will be taken once a week in the morning at least 30-60 minutes before first meal</description>
    <arm_group_label>Placebo Zoledronic Acid &amp; Active Alendronate</arm_group_label>
    <other_name>Fosamax</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo Zoledronic Acid</intervention_name>
    <description>Infusion of placebo zoledronic acid during the first 5 weeks after transplantation</description>
    <arm_group_label>Placebo Zoledronic Acid &amp; Active Alendronate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo Alendronate</intervention_name>
    <description>Placebo alendronate 70 mg once weekly</description>
    <arm_group_label>Active Zoledronic Acid &amp; Placebo Alendronate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A man or woman, aged 20 to 70, of any race who has had a heart or liver transplant

        Exclusion Criteria:

          -  hyperparathyroidism

          -  Paget's disease

          -  hyperthyroidism

          -  cancer

          -  severe kidney disease,

          -  intestinal disease

          -  active peptic ulcer disease

          -  current or past treatment for osteoporosis

          -  pregnancy or lactation

          -  severe oral/dental disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elizabeth Shane, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Shane E, Addesso V, Namerow PB, McMahon DJ, Lo SH, Staron RB, Zucker M, Pardi S, Maybaum S, Mancini D. Alendronate versus calcitriol for the prevention of bone loss after cardiac transplantation. N Engl J Med. 2004 Feb 19;350(8):767-76.</citation>
    <PMID>14973216</PMID>
  </reference>
  <results_reference>
    <citation>Shane E, Cohen A, Stein EM, McMahon DJ, Zhang C, Young P, Pandit K, Staron RB, Verna EC, Brown R, Restaino S, Mancini D. Zoledronic acid versus alendronate for the prevention of bone loss after heart or liver transplantation. J Clin Endocrinol Metab. 2012 Dec;97(12):4481-90. doi: 10.1210/jc.2012-2804. Epub 2012 Sep 28.</citation>
    <PMID>23024190</PMID>
  </results_reference>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 27, 2006</study_first_submitted>
  <study_first_submitted_qc>February 27, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 1, 2006</study_first_posted>
  <results_first_submitted>February 15, 2013</results_first_submitted>
  <results_first_submitted_qc>July 28, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 15, 2016</results_first_posted>
  <last_update_submitted>July 28, 2016</last_update_submitted>
  <last_update_submitted_qc>July 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 15, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Columbia University</investigator_affiliation>
    <investigator_full_name>Elizabeth Shane</investigator_full_name>
    <investigator_title>Professor of Medicine, Endocrinology</investigator_title>
  </responsible_party>
  <keyword>Heart Transplantation</keyword>
  <keyword>Liver Transplantation</keyword>
  <keyword>Immunosuppression</keyword>
  <keyword>Bone Density/drug effects</keyword>
  <keyword>Alendronate</keyword>
  <keyword>Zoledronic acid</keyword>
  <keyword>Comparative study</keyword>
  <keyword>Humans</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bone Resorption</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zoledronic acid</mesh_term>
    <mesh_term>Diphosphonates</mesh_term>
    <mesh_term>Alendronate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Men and women, aged 20 to 70 yr, who had undergone heart or liver transplantation at CUMC were eligible. Of 495 patients transplanted between 3/2006 and 7/2009, 235 were ineligible. 149 patients declined or were not approached. 84 were randomized, 43 to alendronate and 41 to zoledronate. 27 were the reference group since they refused randomization.</recruitment_details>
      <pre_assignment_details>Serum creatinine levels above 2.0 mg/dl, or enrollment in another clinical trial</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Active Zoledronic Acid and Placebo Alendronate</title>
          <description>Group 1 will receive an infusion of active zoledronic acid 5 mg during the first 4 weeks after transplantation. Placebo alendronate 70 mg once weekly will be initiated at the same time as the first zoledronic acid infusion.</description>
        </group>
        <group group_id="P2">
          <title>Placebo Zoledronic Acid and Active Alendronate</title>
          <description>Group 2 will receive an infusion of placebo during the first 5 weeks after transplantation. Active alendronate 70 mg once weekly will be initiated at the same time as the placebo infusion.</description>
        </group>
        <group group_id="P3">
          <title>Reference Group</title>
          <description>The reference group included concurrently transplanted patients with T scores of -1.5 or greater.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Baseline</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
                <participants group_id="P2" count="43"/>
                <participants group_id="P3" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
                <participants group_id="P2" count="43"/>
                <participants group_id="P3" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>6 Month Visit</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
                <participants group_id="P2" count="43"/>
                <participants group_id="P3" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
                <participants group_id="P2" count="41"/>
                <participants group_id="P3" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>12 Month Visit</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
                <participants group_id="P2" count="41"/>
                <participants group_id="P3" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="37"/>
                <participants group_id="P2" count="35"/>
                <participants group_id="P3" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Based on preliminary data that total hip BMD would decrease by 1.5 ± 3.7% on alendronate and increase by 1.0 ± 3.7% on zoledronate, we estimated that 35 subjects per group would provide 80% power and 5% α to detect a 2.5 ± 3.7% difference between randomized groups. Anticipating a 20% dropout, 84 subjects were randomized.</population>
      <group_list>
        <group group_id="B1">
          <title>Active Zoledronic Acid and Placebo Alendronate</title>
          <description>Group 1 will receive an infusion of active zoledronic acid 5 mg during the first 4 weeks after transplantation. Placebo alendronate 70 mg once weekly will be initiated at the same time as the first zoledronic acid infusion.</description>
        </group>
        <group group_id="B2">
          <title>Placebo Infusion and Active Alendronate</title>
          <description>Group 2 will receive an infusion of placebo during the first 5 weeks after transplantation. Active alendronate 70 mg once weekly will be initiated at the same time as the placebo infusion.</description>
        </group>
        <group group_id="B3">
          <title>Reference Group</title>
          <description>The reference group included concurrently transplanted patients with T scores of -1.5 or greater.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="41"/>
            <count group_id="B2" value="43"/>
            <count group_id="B3" value="27"/>
            <count group_id="B4" value="111"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55" spread="8"/>
                    <measurement group_id="B2" value="54" spread="10"/>
                    <measurement group_id="B3" value="48" spread="15"/>
                    <measurement group_id="B4" value="52.9" spread="11.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage Change From Baseline in Total Hip Bone Mineral Density (BMD) at 12 Months</title>
        <description>BMD was measured by dual-energy x-ray absorptiometry (QDR-4500 densitometer; Hologic, Inc., Bedford, MA); short-term in vivo coefficient of variation is 0.68% (spine) and 1.36% (femoral neck). T scores were generated using gender-specific databases provided by the manufacturer.</description>
        <time_frame>Baseline, 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active Zoledronic Acid and Placebo Alendronate</title>
            <description>Group 1 will receive an infusion of active zoledronic acid 5 mg during the first 4 weeks after transplantation. Placebo alendronate 70 mg once weekly will be initiated at the same time as the first zoledronic acid infusion.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Zoledronic Acid and Active Alendronate</title>
            <description>Group 2 will receive an infusion of placebo during the first 5 weeks after transplantation. Active alendronate 70 mg once weekly will be initiated at the same time as the placebo infusion.</description>
          </group>
          <group group_id="O3">
            <title>Reference Group</title>
            <description>The reference group included concurrently transplanted patients with T scores of -1.5 or greater.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change From Baseline in Total Hip Bone Mineral Density (BMD) at 12 Months</title>
          <description>BMD was measured by dual-energy x-ray absorptiometry (QDR-4500 densitometer; Hologic, Inc., Bedford, MA); short-term in vivo coefficient of variation is 0.68% (spine) and 1.36% (femoral neck). T scores were generated using gender-specific databases provided by the manufacturer.</description>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.39" lower_limit="-0.64" upper_limit="1.42"/>
                    <measurement group_id="O2" value="-0.21" lower_limit="-1.25" upper_limit="0.84"/>
                    <measurement group_id="O3" value="-2.2" lower_limit="-3.6" upper_limit="-0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change From Baseline in Lumbar Spine Bone Mineral Density (BMD) at 12 Months</title>
        <description>BMD was measured by dual-energy x-ray absorptiometry (QDR-4500 densitometer; Hologic, Inc., Bedford, MA); short-term in vivo coefficient of variation is 0.68% (spine) and 1.36% (femoral neck). T scores were generated using gender-specific databases provided by the manufacturer.</description>
        <time_frame>Baseline, 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active Zoledronic Acid and Placebo Alendronate</title>
            <description>Group 1 will receive an infusion of active zoledronic acid 5 mg during the first 4 weeks after transplantation. Placebo alendronate 70 mg once weekly will be initiated at the same time as the first zoledronic acid infusion.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Zoledronic Acid and Active Alendronate</title>
            <description>Group 2 will receive an infusion of placebo during the first 5 weeks after transplantation. Active alendronate 70 mg once weekly will be initiated at the same time as the placebo infusion.</description>
          </group>
          <group group_id="O3">
            <title>Reference Group</title>
            <description>The reference group included concurrently transplanted patients with T scores of -1.5 or greater.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change From Baseline in Lumbar Spine Bone Mineral Density (BMD) at 12 Months</title>
          <description>BMD was measured by dual-energy x-ray absorptiometry (QDR-4500 densitometer; Hologic, Inc., Bedford, MA); short-term in vivo coefficient of variation is 0.68% (spine) and 1.36% (femoral neck). T scores were generated using gender-specific databases provided by the manufacturer.</description>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.98" lower_limit="0.55" upper_limit="3.40"/>
                    <measurement group_id="O2" value="-0.45" lower_limit="-1.88" upper_limit="0.99"/>
                    <measurement group_id="O3" value="-2.6" lower_limit="-4.4" upper_limit="-0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change From Baseline in Femoral Neck Bone Mineral Density (BMD) at 12 Months</title>
        <description>BMD was measured by dual-energy x-ray absorptiometry (QDR-4500 densitometer; Hologic, Inc., Bedford, MA); short-term in vivo coefficient of variation is 0.68% (spine) and 1.36% (femoral neck). T scores were generated using gender-specific databases provided by the manufacturer.</description>
        <time_frame>Baseline, 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Active Zoledronic Acid and Placebo Alendronate</title>
            <description>Group 1 will receive an infusion of active zoledronic acid 5 mg during the first 4 weeks after transplantation. Placebo alendronate 70 mg once weekly will be initiated at the same time as the first zoledronic acid infusion.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Zoledronic Acid and Active Alendronate</title>
            <description>Group 2 will receive an infusion of placebo during the first 5 weeks after transplantation. Active alendronate 70 mg once weekly will be initiated at the same time as the placebo infusion.</description>
          </group>
          <group group_id="O3">
            <title>Reference Group</title>
            <description>The reference group included concurrently transplanted patients with T scores of -1.5 or greater.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change From Baseline in Femoral Neck Bone Mineral Density (BMD) at 12 Months</title>
          <description>BMD was measured by dual-energy x-ray absorptiometry (QDR-4500 densitometer; Hologic, Inc., Bedford, MA); short-term in vivo coefficient of variation is 0.68% (spine) and 1.36% (femoral neck). T scores were generated using gender-specific databases provided by the manufacturer.</description>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="35"/>
                <count group_id="O3" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.28" lower_limit="-1.16" upper_limit="1.71"/>
                    <measurement group_id="O2" value="-0.57" lower_limit="-2.02" upper_limit="0.88"/>
                    <measurement group_id="O3" value="-3.3" lower_limit="-4.8" upper_limit="-1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum N-telopeplide Percent Change</title>
        <time_frame>24 months</time_frame>
        <population>Zero participants were analyzed because data was not collected. This was not a prespecified secondary outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>Active Zoledronic Acid and Placebo Alendronate</title>
            <description>Group 1 will receive an infusion of active zoledronic acid 5 mg during the first 4 weeks after transplantation. Placebo alendronate 70 mg once weekly will be initiated at the same time as the first zoledronic acid infusion.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Zoledronic Acid and Active Alendronate</title>
            <description>Group 2 will receive an infusion of placebo during the first 5 weeks after transplantation. Active alendronate 70 mg once weekly will be initiated at the same time as the placebo infusion.</description>
          </group>
          <group group_id="O3">
            <title>Reference Group</title>
            <description>The reference group included concurrently transplanted patients with T scores of -1.5 or greater.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum N-telopeplide Percent Change</title>
          <population>Zero participants were analyzed because data was not collected. This was not a prespecified secondary outcome.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Active Zoledronic Acid and Placebo Alendronate</title>
          <description>Group 1 will receive an infusion of active zoledronic acid 5 mg during the first 4 weeks after transplantation. Placebo alendronate 70 mg once weekly will be initiated at the same time as the first zoledronic acid infusion.</description>
        </group>
        <group group_id="E2">
          <title>Placebo Infusion and Active Alendronate</title>
          <description>Group 2 will receive an infusion of placebo during the first 5 weeks after transplantation. Active alendronate 70 mg once weekly will be initiated at the same time as the placebo infusion.https://register.clinicaltrials.gov/prs/html/results_definitions.html#Result_ParticipantFlow_Period_title</description>
        </group>
        <group group_id="E3">
          <title>Reference Group</title>
          <description>The reference group included concurrently transplanted patients with T scores of -1.5 or greater.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Hospitalization</sub_title>
                <description>Includes all hospital readmissions after randomization or enrollment.</description>
                <counts group_id="E1" events="20" subjects_affected="20" subjects_at_risk="41"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="41"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="43"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <description>Albumin-corrected serum calcium below 8.0 mg/dL.
To convert values for serum calcium to millimoles per liter, multiply by 0.2495.</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Serum Calcium &gt; 2.0 mg/dL</sub_title>
                <description>At any visit after randomization. To convert values for serum creatinine to millimoles per liter, multiply by 88.4.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Rejection</sub_title>
                <description>Rejection after month 1 necessitating change in immunosuppressive regimen</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Flu-like symptoms after zoledronate or matching placebo</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <description>Includes all infections due to cytomegalovirus and all other infections that necessitated hospitalization, intravenous antibiotic therapy, or both.</description>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="41"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="43"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Heart and liver transplant recipients differ in pretransplant bone disease and exposure to prednisone. Not powered to detect differences in fracture rates,an important clinical outcome,one that would require a large comparative effectiveness trial.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Elizabeth Shane</name_or_title>
      <organization>Columbia University</organization>
      <phone>2123056289</phone>
      <email>es54@columbia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

